COVAX

Scientists around the world are working at an unprecedented pace to test different types of vaccines that could help to stop the spread of COVID-19.

Here’s how Gavi helps lower-income countries get the new vaccines and products they need to address urgent threats to public health – from cholera and COVID-19, to Ebola and pneumonia.

President of Niger H.E. Issoufou Mahamadou talks about the importance of routine immunisation and Gavi support in Niger, and the need for ensuring universal access to COVID-19 vaccines through the COVAX Facility.

Most vaccine candidates in early development fail: this is the stark reality of vaccine development.

Gavi’s CEO explains how its Advance Market Commitment mechanism will make COVID-19 vaccines available to lower-income countries.

The UK is expected to host the world’s first COVID-19 human “challenge” trials, which will involve deliberately infecting healthy volunteers with coronavirus to assess the effectiveness of experimental vaccines. So far, around 2,000 potential volunteers have signed up. But do how do we ensure the benefits outweigh the risks?

Vaccine manufacturers have worked hard to adapt to a new normal of keeping supplies for immunisation programmes going in the midst of the COVID-19 pandemic.

At the beginning of the pandemic there was a mad scramble to develop a test which would accurately diagnose COVID-19 infection. Now, six months in, hundreds of testsare available – but how do they differ, and which test is the most appropriate for which scenario?

Gavi’s Derrick Sim, Director of Vaccine Supply and Demand, discusses why it is sometimes important to halt clinical trials.

Some researchers conducting clinical trials on a COVID-19 vaccine have not revealed to the public what the placebo contains, but they should.